Clinical Trials Logo

Epiretinal Membrane clinical trials

View clinical trials related to Epiretinal Membrane.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04130841 Active, not recruiting - Retinal Disease Clinical Trials

Effects of Internal Limiting Membrane Peeling on Visual Function in Epiretinal Membrane Surgery

Start date: September 30, 2019
Phase: N/A
Study type: Interventional

The patients who are diagnosed with idiopathic epiretinal membrane and scheduled to undergo epiretinal membrane removal will be treated with conventional vitrectomy and the epiretinal membrane will be removed. After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.

NCT ID: NCT04120636 Active, not recruiting - Epiretinal Membrane Clinical Trials

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Start date: March 5, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the retina, choroid and vitreous.

NCT ID: NCT04120311 Active, not recruiting - Macular Edema Clinical Trials

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Start date: September 1, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.

NCT ID: NCT02328157 Active, not recruiting - Cataract Clinical Trials

Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.

Start date: January 2015
Phase: N/A
Study type: Interventional

Toric intraocular lens (IOL) is now widely used for the cataract surgery with preoperative corneal astigmatism. Symptomatic epiretinal membrane (ERM) is often treated with 25-gauge transconjunctival sutureless vitrectomy, resulting in good visual recovery. So far, however, limited information is available on the the stability of axis rotation, astigmatism correction, and improvement in uncorrected distance visual acuity, using astigmatism-correcting IOL in a 25-gauge transconjunctival sutureless vitrectomy combined with cataract surgery. In the current study, eyes with a preoperative corneal cylinder of more than 0.75 diopter had a triple procedure for idiopathic ERM using a toric IOL. Outcome measures will be the amount of IOL axis rotation, uncorrected visual acuity, corrected distance visual acuity, and corneal and refractive astigmatism up to 6 months postoperatively. We are expecting to show that postoperative IOL axis stability is similar to that reported for cataract surgery alone in vitrectomy (triple procedure) for idiopathic ERM with a toric IOL.

NCT ID: NCT01969929 Active, not recruiting - Macular Hole Clinical Trials

Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy

20Gvs23G
Start date: October 2013
Phase: N/A
Study type: Interventional

To compare postoperative inflammation and breakdown of blood-retinal barrier as measured by a laser flare-cell meter in 20G versus 23G vitrectomy.

NCT ID: NCT01946451 Active, not recruiting - Clinical trials for Proliferative Diabetic Retinopathy

Gene Expression in Patients With Epiretinal Membranes

Start date: June 2012
Phase: N/A
Study type: Observational

The purpose of this study was to investigate the expression of selected genes both in epiretinal membranes (ERMs) and peripheral blood mononuclear cells (PBMCs) from patients with primary and secondary epiretinal membranes in proliferative diabetic retinopathy. Possible correlations between messenger ribonucleic acid (mRNA) levels of these genes were also identified.